[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Distler M, Rückert F, Dittert DD, Stroszczynski C, Dobrowolski F, Kersting S, Grützmann R: Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol; 2009;7:22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
  • At the time of diagnosis only 50% of the tumors appear to be resectable.
  • Reliable data for an effective adjuvant or neoadjuvant treatment are not available.
  • MRI-imaging showed a tumor within the head of the pancreas concomitant with Serum-Lipase and CA19-9.
  • Laparotomy presented an locally advanced tumor with venous infiltration that was consequently deemed unresectable.
  • Chemotherapy was well tolerated, and no severe complications were observed.
  • Twelve months later, the patient was in stable condition, and CT-scanning showed an obvious reduction in the size of the tumor.
  • Histopathological examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to be negative.
  • Therefore, neoadjuvant chemotherapy could be an option to reduce a primarily unresectable ACC to a point where curative resection can be achieved.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / surgery. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • (PMID = 19239719.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2657786
  •  go-up   go-down


2. Hashimoto M, Umekita N, Noda K: Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report. World J Gastroenterol; 2008 Jul 7;14(25):4093-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) revealed a 10 cm mass in the retroperitoneal space behind the head of the pancreas causing obstruction of the distal bile duct and the PV.
  • The pathologic diagnosis was diffuse large B-cell type non-Hodgkin lymphoma and the patient was transferred to the Department of Hematology and Oncology for chemotherapy.
  • He received four cycles of combined chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab, and three cycles of intrathecal chemoprophylaxis including methotorexate, cytosine arbinoside and prednisone.
  • The patient is alive with no evidence of the disease for 7 mo after operation and will receive additional courses of chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Bile Ducts / pathology. Chemotherapy, Adjuvant. Humans. Jugular Veins / transplantation. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1188-94 [10811326.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):43-9 [11466812.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2003;33(1):72-4 [12560914.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2323-32 [17406815.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 May 1;71(9):2813-6 [7682150.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):813-9 [17440790.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):503-7 [1323924.001]
  • (PMID = 18609698.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725353
  •  go-up   go-down


3. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM: Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. Haematologica; 2006 Dec;91(12 Suppl):ECR55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
  • A CT scan of the abdomen demonstrated an enlargement of the head and uncinate of pancreas and diffuse lymphadenopathy.
  • The patient developed respiratory distress and expired.
  • An autopsy of the pancreas revealed clusters of large, atypical cells, which morphologically and immunophenotypically were consistent with CD30 positive, ALK-negative anaplastic large cell lymphoma (ALCL) of T-cell lineage and multifocal fat necrosis (panniculitis) in the peripancreatic adipose tissue.
  • This is the first case of ALCL of the pancreas and panniculitis in a patient with history of AML.
  • [MeSH-major] Leukemia, Myeloid / drug therapy. Lymphoma, Large-Cell, Anaplastic / diagnosis. Neoplasms, Second Primary / diagnosis. Pancreas / pathology. Panniculitis / etiology
  • [MeSH-minor] Acute Disease. Aged. Fatal Outcome. Humans. Male. Neoplasm Proteins / analysis. Respiratory Insufficiency / etiology


Advertisement
4. Kodjikian L, Grange JD, Rivoire M: Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):622-4
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
  • METHODS: A 30-year-old patient, treated for choroidal melanoma by proton beam therapy, was semiannually followed by abdominal ultrasonography.
  • Two years after initial treatment, a total body computed tomography scan suggested the diagnosis of isolated liver metastases.
  • RESULTS: Multiple wedge resections and postoperative intra-arterial chemotherapy with fotemustine were performed.
  • After 4 years, a metastatic nodule in the head of the pancreas was detected and surgically removed.
  • The patient finally died of carcinomatous meningitis 9 years of first treatment of metastases.
  • CONCLUSIONS: In the present case, the surgical control of liver metastases associated with intra-arterial chemotherapy prolonged the quality and length of life with progressive disease extension to other organs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatectomy / methods. Liver Neoplasms / mortality. Melanoma / mortality. Uveal Neoplasms / mortality
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Fatal Outcome. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Neoplasm Metastasis. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):127-30 [9591028.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S27-30 [9849406.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):122-9 [14692032.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Arch Ophthalmol. 1984 Jan;102(1):80-2 [6200095.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2219-23 [7848381.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):207-8; author reply 208 [15222009.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1561-8 [11013372.001]
  • [Cites] Am J Ophthalmol. 1998 Mar;125(3):407-9 [9512169.001]
  • (PMID = 15650857.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 7GR28W0FJI / Dacarbazine; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


5. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a (125)iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.
  • The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05).
  • The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176).
  • All the patients recovered well after conservative support treatment.
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.
  • [MeSH-major] Adenocarcinoma / therapy. Catheter Ablation / methods. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


6. Saif MW: Primary pancreatic lymphomas. JOP; 2006;7(3):262-73
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, primary pancreatic lymphomas usually present with symptoms of carcinoma of the pancreatic head.
  • An accurate cytopathologic diagnosis by fine-needle aspiration (FNA) is imperative because the primary treatment is non-surgical.
  • FNA coupled with flow cytometry analysis appears to be highly accurate in the diagnosis of primary pancreatic lymphomas.
  • Fluorescence in-situ hybridisation technique has been established its role in the diagnosis of lymphoid malignancies, including primary pancreatic lymphomas.
  • LDH and beta-2 microglobulin are important diagnostic and prognostic tumor markers.
  • The differential diagnoses of primary pancreatic lymphomas include secondary lymphoma, pancreatic endocrine neoplasm, and florid chronic pancreatitis.
  • Treatment usually consists of a combination of chemotherapy and radiation therapy, or stem cell transplantation.
  • Primary pancreatic lymphomas has a much better prognosis than adenocarcinoma of the pancreas.
  • [MeSH-major] Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685107.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 40
  •  go-up   go-down


7. Bauditz J, Rudolph B, Wermke W: Osteoclast-like giant cell tumors of the pancreas and liver. World J Gastroenterol; 2006 Dec 28;12(48):7878-83
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-like giant cell tumors of the pancreas and liver.
  • Osteoclast-like giant cell tumors (OGCT) are rare abdominal tumors, which mainly occur in the pancreas.
  • Here we report on two cases of osteoclast-like giant cell tumors, one located within the pancreas, the other within the liver, in which OGCTs are extremely rare.
  • Both patients were investigated by contrast sonography, which demonstrated a complex, partly cystic and strongly vascularized tumor within the head of the pancreas in the first patient and a large, hypervascularized neoplasm with calcifications within the liver in the second patient.
  • With a combination of surgical resection, radiofrequency ablation and chemotherapy, the patient's survival is currently more than 15 mo, making him the longest survivor with an OGCT of the liver to date.
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):516-20 [15953882.001]
  • [Cites] Int J Clin Oncol. 2002 Dec;7(6):376-80 [12494256.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):761-6 [15209622.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Cancer. 1977 Mar;39(3):1181-9 [912652.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):771-9 [6994872.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):837-42 [6331629.001]
  • [Cites] Tumori. 1985 Dec 31;71(6):615-20 [3001983.001]
  • [Cites] Acta Pathol Jpn. 1987 Aug;37(8):1327-35 [3673575.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):111-6 [2153001.001]
  • [Cites] Cancer. 1992 May 15;69(10):2444-8 [1314689.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Histopathology. 1993 Aug;23(2):187-9 [8406392.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1055-7 [8281385.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):334-5 [8634058.001]
  • [Cites] Pathol Int. 1997 May;47(5):318-24 [9143028.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):215-8 [9334844.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1247-54 [9777987.001]
  • [Cites] Pancreas. 1999 Apr;18(3):308-15 [10206490.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):207-14 [15694816.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Pancreatology. 2005;5(2-3):279-84 [15849490.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):77-80 [11232955.001]
  • (PMID = 17203538.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087560
  •  go-up   go-down


8. Nishimori H, Takahashi S, Nagasaki E, Kobayashi T, Yokoyama M, Shinozaki E, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Inamura K, Hatake K: [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]. Gan To Kagaku Ryoho; 2005 May;32(5):671-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
  • A 40-year-old man suffering from right cheek swelling was first diagnosed with ameloblastoma or anaplastic poorly-differentiated carcinoma of the head and neck region.
  • He received 2 courses of CDDP/TXT chemotherapy (cisplatin 75 mg/m2, docetaxel 80 mg/m2) and achieved a partial response, but his carcinoma of the pancreas recurred.
  • The autopsy revealed a pathological diagnosis of metastatic endocrine carcinoma of the pancreas.
  • This case was close to a cancer with an unknown primary (CUP) site, and several favorable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy.
  • Poorly-differentiated neuroendocrine carcinomas like this case are highly sensitive to chemotherapy, and a careful pathological diagnosis may clarify its sensitivity to chemotherapy and the prognosis.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918570.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Ohmura T, Umekita N, Ohkubo T, Tanaka S, Maeshiro T, Matsuo S, Miyamoto S, Inoue S, Kitamura M: [Local recurrence of pancreatic cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho; 2005 Feb;32(2):239-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient for whom systemic chemotherapy using gemcitabine was effective against local recurrence of pancreatic cancer.
  • A 58-year-old man underwent pancreatoduodenectomy for a pancreatic head cancer.
  • The diagnosis was Stage IVb poorly-differentiated tubular adenocarcinoma, scirrhous type, pT4, PL (+), P0, H0, pN2.
  • Gastroscopy and CT examination revealed a mass at the cut-end of the pancreas invading the stomach.
  • Systemic chemotherapy was performed with a regimen of gemcitabine 1,000 mg/m2/week for 2 weeks, followed by a week rest.
  • The recurrent tumor in the stomach disappeared, and the mass at the cut-end of the pancreas became small.
  • Two years after the diagnosis of recurrence, he returned to work, and his chemotherapy is being continued as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Male. Middle Aged. Pancreaticoduodenectomy. Postoperative Period. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751641.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Obuchi T, Sasaki A, Shimooki O, Minakawa Y, Abe T, Nitta H, Otsuka K, Koeda K, Ikeda K, Wakabayashi G: [Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):991-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient for whom systemic chemotherapy using gemcitabine was effective against local recurrence of pancreatic cancer.
  • A 59-year-old man underwent pancreatoduodenectomy for pancreatic head cancer.
  • The diagnosis was moderately-differentiated tubular adenocarcinoma(tubular type, pT2, pN0, fM0, fStage II ).
  • Ten months after surgery, the patient had a CT examination which revealed a mass at the cut-end of the pancreas.
  • Chemotherapy with GEM(1,000 mg/m2)was administered intravenously on days 1, 8, and 15.
  • The patient received 8 courses of chemotherapy by GEM, and the regimen was changed to every two weeks because of the adverse event, leucopenia(grade 2)and thrombocytopenia( grade 2).
  • Twenty-one months after chemotherapy, CT examination revealed regrowth at the same location at the cut-end of the pancreas, and so radiotherapy was performed at a total 63 Gy.
  • The patient had been receiving systemic chemotherapy as an outpatient for 48 months without deterioration of quality of life.
  • Our experience suggests that this chemotherapy is simple and possible to continue safely on an ambulatory basis while maintaining quality of life.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; B76N6SBZ8R / gemcitabine; 1-UFT protocol
  •  go-up   go-down


11. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Schütte K, Bornschein J, Kuester D, Wieners G, Malfertheiner P: [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head]. Med Klin (Munich); 2010 Apr;105(4):291-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head].
  • The reason was an arterial hemorrhage from a duodenal tumor that could only be stopped by an angiographic intervention.
  • In the further staging, there was evidence for a neuroendocrine carcinoma of the pancreatic head with infiltration of the duodenum and hepatic metastases.
  • After recurrent bleeding with arrosion of a branch of the superior mesenteric artery, a duodenum-preserving pancreatic head resection was performed.
  • Afterwards, the systemic therapy was changed to a palliative chemotherapy with streptozotocin and 5-fluorouracil due to local progression of the disease and a Ki-67 index of 4% in the primary tumor.
  • CONCLUSION: In about 0.7% of patients with neuroendocrine tumors, the lesion is located in the pancreas.
  • The therapy depends on the local spread and histological grading as well as symptoms of the patient.
  • However, even in a palliative situation, there can be benefit for the patient in case of a tumor mass reduction of > 90%.
  • Alternative therapies in the palliative situation are somatostatin analogs, a classic systemic chemotherapy, or locoregional interventional procedures.
  • [MeSH-major] Duodenum / pathology. Gastrointestinal Hemorrhage / etiology. Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Endoscopy, Digestive System. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):221-32 [17639039.001]
  • [Cites] J Clin Gastroenterol. 2006 Aug;40(7):572-82 [16917396.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • (PMID = 20455052.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084961.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • A laparoscopic biopsy out of a suspicious lesion of the head of the pancreas and a surrounding lymph node was done.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • CONCLUSION: This case shows a seminoma with metastases at retroperitoneal site, mimicking a primary pancreatic neoplasm.
  • It provides an example of the possibility of an uncommon clinical appearance of seminoma metastases and again underlines the importance of exact radiological and histopathological examination to distinguish between curable and incurable tumor.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


17. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D: Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol; 2006 Oct;82(10):699-757
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.
  • PURPOSE: The Cancer Imaging Program of the National Cancer Institute convened a workshop to assess the current status of hypoxia imaging, to assess what is known about the biology of hypoxia as it relates to cancer and cancer therapy, and to define clinical scenarios in which in vivo hypoxia imaging could prove valuable.
  • RESULTS: Hypoxia, or low oxygenation, has emerged as an important factor in tumor biology and response to cancer treatment.
  • It has been correlated with angiogenesis, tumor aggressiveness, local recurrence, and metastasis, and it appears to be a prognostic factor for several cancers, including those of the cervix, head and neck, prostate, pancreas, and brain.
  • The relationship between tumor oxygenation and response to radiation therapy has been well established, but hypoxia also affects and is affected by some chemotherapeutic agents.
  • Although hypoxia is an important aspect of tumor physiology and response to treatment, the lack of simple and efficient methods to measure and image oxygenation hampers further understanding and limits their prognostic usefulness.
  • CONCLUSIONS: This workshop yielded recommendations on using hypoxia measurement to identify patients who would respond best to radiation therapy, which would improve treatment planning.
  • This represents a narrow focus, as hypoxia measurement might also prove useful in drug development and in increasing our understanding of tumor biology.
  • [MeSH-major] Anoxia / diagnosis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnostic Imaging / methods. Neoplasms / drug therapy. Oxygen / metabolism
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / analysis. Carbonic Anhydrases / metabolism. Humans. Hypoxia-Inducible Factor 1 / metabolism. Isoenzymes / metabolism. National Institutes of Health (U.S.). Prognosis. Reproducibility of Results. United States

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118889.001).
  • [ISSN] 0955-3002
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA042045
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Hypoxia-Inducible Factor 1; 0 / Isoenzymes; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; S88TT14065 / Oxygen
  • [Number-of-references] 337
  •  go-up   go-down


18. Calabrese L, Jereczek-Fossa BA, Jassem J, Rocca A, Bruschini R, Orecchia R, Chiesa F: Diagnosis and management of neck metastases from an unknown primary. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):2-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of neck metastases from an unknown primary.
  • Metastases in the upper and middle neck (levels I-II-III-V) are generally attributed to head and neck cancers, whereas the lower neck (level IV) involvement is often associated with primaries below the clavicles.
  • Diagnostic procedures include a careful clinical evaluation and a fiberoptic endoscopic examination of the head and neck mucosa, biopsies from all suspicious sites or blindly from the sites of possible origin of the primary, computerized tomography scan, and magnetic resonance.
  • Thoracic, and abdominal primaries (especially from lung, oesophagus, stomach, ovary or pancreas) should be sought in the case of adenocarcinoma and involvement of the lower neck.
  • Positron emission tomography with fluoro-2-deoxy-D-glucose allows detection of primary tumour in about 25% of cases, but this procedure is still considered investigational.
  • Therapeutic approaches include surgery (neck dissection), with or without post-operative radiotherapy, radiotherapy alone and radiotherapy followed by surgery as reported by several guide-lines.
  • The role of other methods, such as chemotherapy and hyperthermia, remains to be determined.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):411-6 [12634970.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Sep;260(8):436-43 [12684829.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Oct;260(9):490-3 [12739031.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Cancer Treat Rev. 2004 Jun;30(4):369-84 [15145511.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Radiology. 1974 Mar;110(3):659-63 [4130047.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):517-22 [911038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):73-6 [422418.001]
  • [Cites] Clin Radiol. 1980 May;31(3):355-8 [7428277.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 May;12(5):733-40 [3710857.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Jun;94(5):605-10 [3088524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2101-10 [3793546.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Acta Oncol. 2001;40(1):24-8 [11321655.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):214-6 [11408815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):4-9 [11516844.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1057-8 [11583184.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1605-9 [11822762.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):289-94 [2303361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):919-28 [2211260.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1388-93 [2248737.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):463-9 [2258284.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):177-83 [2037468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):619-22 [8454479.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1756-61 [8348505.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):58-63 [8125789.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):119-47 [8156538.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):395-9 [7977958.001]
  • [Cites] Laryngoscope. 1995 May;105(5 Pt 1):548-50 [7760677.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):190-8 [7782203.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):222-8 [7546677.001]
  • [Cites] Radiother Oncol. 1995 Jun;35(3):206-11 [7480823.001]
  • [Cites] Radiology. 1996 Jun;199(3):761-6 [8638002.001]
  • [Cites] J Laryngol Otol. 1996 Apr;110(4):353-6 [8733457.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1996;113(4):212-8 [9033687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):797-802 [9128954.001]
  • [Cites] Strahlenther Onkol. 1997 Jul;173(7):362-8 [9265258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):291-6 [9308930.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):322-9 [9368728.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):121-5 [9537194.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1998 Apr;23(2):158-63 [9597287.001]
  • [Cites] Laryngoscope. 1998 Oct;108(10):1578-83 [9778305.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):33-40 [9886695.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):114-8 [10391570.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):700-4 [10435932.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):214-8 [10439166.001]
  • [Cites] Oncologist. 2005 Mar;10(3):215-24 [15793225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jan;122(1):52-5 [10629482.001]
  • [Cites] Int J Hyperthermia. 2000 Jan-Feb;16(1):85-93 [10669319.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):263-8 [10779057.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2000 May;103(5):524-8 [10853340.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301 [10964310.001]
  • [Cites] Otolaryngol Pol. 2000;54 Suppl 31:258-61 [10974901.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2002;56(1):77-82 [11894635.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):323-9 [11981279.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30 [12173016.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):569-74 [12206272.001]
  • [Cites] Cancer Control. 2002 Sep-Oct;9(5):387-99 [12410178.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Dec;40(6):484-7 [12464205.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Head Neck. 2003 Feb;25(2):138-45 [12509797.001]
  • [Cites] Acta Otorrinolaringol Esp. 2002 Oct;53(8):601-6 [12530200.001]
  • (PMID = 16080309.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 102
  • [Other-IDs] NLM/ PMC2639847
  •  go-up   go-down


19. Fischer L, Friess H, Z'graggen K, Uhl W, Büchler MW: [Operative management in the treatment of pancreatic cancer]. Zentralbl Chir; 2003 May;128(5):390-5
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative management in the treatment of pancreatic cancer].
  • [Transliterated title] Operatives Management bei der Therapie des Pankreaskarzinoms.
  • The carcinoma of the pancreas is one of the 10 leading causes of death in the Western countries.
  • Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure.
  • However, about 80 % of patients with the diagnosis of pancreatic cancer are no more suitable for curative resection at the time of diagnosis because of local tumor infiltration or the presence of distant metastases.
  • In resectable tumors of the pancreas head the standard Whipple dominates still as the surgical method of choice.
  • The prospective European multicenter study ESPAC-1 firstly demonstrated a survival advantage for adjuvant chemotherapy (5-FU and folic acid) but no gain for radiochemotherapy in the treatment of patients with R0 or R1 resected pancreatic cancer in terms of prolongation of mean survival (19.7 months vs. 14.0 months).
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Therapy, Combination. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Hematinics / administration & dosage. Hematinics / therapeutic use. Humans. Multicenter Studies as Topic. Neoplasm Metastasis. Pancreaticoduodenectomy. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12813637.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hematinics; 935E97BOY8 / Folic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G: Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain. Onkologie; 2009 Mar;32(3):119-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We here report a case of devastating extramedullary relapse of IgA/lambdaMM (stage IA) treated at diagnosis with a dexamethasone, adriamycin, vincristine (DAV) regimen followed by high-dose therapy and autologous stem cell transplantation (ASCT), achieving a partial remission.
  • After 6 years of stable disease, the patient presented symptoms of obstructive jaundice determined by a large mass of the head of the pancreas.
  • RESULTS: We observed a progression of disease despite an aggressive treatment with high-dose cyclophosphamide.
  • CONCLUSIONS: Our case shows that extramedullary relapses of MM after ASCT are very resistant to conventional chemotherapy.
  • The role of new drugs and the optimal treatment strategy in these cases remain to be defined.
  • [MeSH-major] Abdominal Pain / prevention & control. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Immunoglobulin lambda-Chains / analysis. Jaundice, Obstructive / prevention & control. Multiple Myeloma / drug therapy. Neoplasm Recurrence, Local / prevention & control. Pancreatic Neoplasms / drug therapy


21. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • Specific information regarding intraductal papillary mucinous neoplasm (IPMN) recurrence is limited because most series are small and the follow-up interval is short.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • The patient did not receive postoperative chemotherapy and was monitored with transaxial imaging at regular intervals.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country.
  • Most patients present with obstructive jaundice caused by compression of the bile duct in the head of the pancreas.
  • More than one half of cases have distant metastasis at diagnosis.
  • Computed tomography is the most useful diagnostic and staging tool.
  • The majority of tumors are not surgically resectable because of metastasis and invasion of the major vessels posterior to the pancreas.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Adjuvant fluorouracil-based chemotherapy may prolong survival.
  • For nonresectable tumors, chemotherapy with gemcitabine prolongs survival.
  • Radiation combined with chemotherapy has slowed progression in locally advanced cancers.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


23. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • CT is the most important way of diagnosis and the combination of B-ultrasound, CT and MRI may improve the rate of diagnosis up to 96.6%.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol; 2001 Mar;8(2):123-32
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
  • BACKGROUND: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy.
  • The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors. and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head.
  • METHODS: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database.
  • Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine).
  • All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence.
  • RESULTS: The overall median survival from the time of tissue diagnosis was 21 months (range 19-26, 95%CI).
  • There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect.
  • Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks).
  • Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / epidemiology. Paclitaxel / administration & dosage. Pancreatectomy / adverse effects. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11258776.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E: Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. J Surg Oncol; 2001 Apr;76(4):289-96
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature.
  • BACKGROUND: Solid-pseudopapillary tumor of the pancreas (SPT) is an exceptionally rare neoplasm in children.
  • PATIENTS AND METHODS: A cumulative review of the tumor's clinicopathological characteristics from the world's literature is presented.
  • Two tumors were located in the tail, one in the body and tail and one in the head of the pancreas (diameter: 7--15 cm).
  • Surgical procedures included three distal pancreatectomies and one partial duodenopancreatectomy (Whipple procedure).
  • Chemotherapy was initiated for this patient.
  • CONCLUSIONS: SPT is a rare differential diagnosis of a pancreatic mass in children.
  • It is mandatory to establish this diagnosis since complete surgical removal of the tumor even in case of metastases or local invasion offers an excellent prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11320522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


26. Haji AG, Sharma S, Majeed KA, Vijaykumar DK, Pavithran K, Dinesh M: Primary pancreatic lymphoma: Report of three cases with review of literature. Indian J Med Paediatr Oncol; 2009 Jan;30(1):20-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary pancreatic lymphoma (PPL) is an extremely rare neoplasm, which may be confused with pancreatic adenocarcinoma.
  • Two patients had diagnosis confirmed histologically by CT-guided core biopsy or Fine needle aspiration procedure.
  • We were able to avoid unnecessary laparotomy in 2 patients using preoperative guided Fine needle aspiration Cytology, although the third patient did undergo a Whipple's procedure as the diagnosis of PPL was not considered during the initial workup.
  • The differential diagnosis of PPL includes pancreatic adenocarcinoma and secondary involvement of pancreas from extra-nodal lymphoma.
  • (1) Bulky localized tumor in pancreatic head (2) Absence of significant dilatation of main pancreatic duct strengthens a diagnosis of pancreatic lymphoma over adenocarcinoma.
  • Majority of patients can be managed with chemotherapy with much better prognosis compared to patients with pancreatic adenocarcinoma.
  • Larger series of patients are needed to evaluate whether chemotherapy, eventually followed by involved-field radiation therapy, is the treatment of choice for PPL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1993 Aug;59(8):513-8 [8338282.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):80-2 [9577380.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):834-6 [9622727.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):671-5 [10701607.001]
  • [Cites] Surg Endosc. 2002 Jul;16(7):1107-8 [11984658.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • [Cites] Rinsho Ketsueki. 2002 Apr;43(4):292-7 [12043211.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] Pancreas. 1992;7(1):118-20 [1557340.001]
  • [Cites] Arch Surg. 1989 Nov;124(11):1287-9 [2818182.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):109-12 [8877636.001]
  • (PMID = 20668602.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2902210
  • [Keywords] NOTNLM ; Pancreatic lymphoma / neoplasm / pancreatic adenocarcinoma
  •  go-up   go-down


27. Michalet V, Gaudin JL, Bancel B, El Khaddari S, Baulieux J, Rode A, Souquet JC: [Squamous cell carcinoma of the celiac area. Report of a case and review of the literature]. Gastroenterol Clin Biol; 2002 Dec;26(12):1168-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary squamous cell carcinoma of the pancreas or of the stomach is rare and represents a controversial entity.
  • The unusual case of a 50-year-old woman with a large squamous cell carcinoma located in the celiac area and involving liver, stomach and pancreas, is reported here.
  • The microscopic diagnosis was well-differentiated squamous cell carcinoma without glandular structure.
  • Following the procedure, search for another possible primary lesion (esophagus, anus, colon, lung, head and neck, pelvic floor) was performed.
  • In this context, final diagnosis was primary gastric or pancreatic squamous cell carcinoma.
  • Subsequent radiation combined with chemotherapy was instituted, allowing complete remission.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520205.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 15
  •  go-up   go-down






Advertisement